

## Cerbios-Pharma publishes its first Sustainability Report. A commitment towards becoming more sustainable, day after day.

Lugano, September 1<sup>st</sup>, 2016. The management of Cerbios-Pharma SA (from now on “Cerbios”) is proud to announce the release of its first Sustainability Report, published according to the guidelines and framework of the Global Reporting Initiative.

*“We are really pleased to share with all our stakeholders the positive progress we are making towards embedding sustainability principles in everything we do” confirms Gabriel Haering, CEO. “We have always believed that our commitments do beyond our shareholders and our economic results and in this document we lay out how we take up the challenge of pursuing the Triple Bottom Line and the subsequent economic, environmental and social objectives and commit for the future”.*

With this report we want to show who we are, what we do and how we do it with the maximum transparency possible.

We believe that organizations can be a real agent for change and a Force for Good in a society and an environment at risk of degradation.

We hope you will enjoy the electronic reading ([follow this link](#)) and we look forward to receiving your comments and feedback. The printed version will be available at Cerbios’ Booth 2L30 (Hall 2) during CPhI in Barcelona, October 4-6.



### Sustainability Report



For further information, please contact:

**Cerbios-Pharma SA**

Via Figino 6  
6917 Barbengo/Lugano  
SWITZERLAND

Phone +41 (0) 91 985 63 11  
Fax +41 (0) 91 985 63 25  
email [info@cerbios.ch](mailto:info@cerbios.ch)

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India